Role of non-classical MHC class I molecules in cancer immunosuppression

OncoImmunology

Volumn 2, Issue 11, 2013, Pages

  Kochan, Grazyna ^a   Escors, David ^a,b   Breckpot, Karine ^c   Guerrero Setas, David ^a  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antigen presentation; Cancer; Immunomodulation; NK cells; Non classical MHC class I molecules; T cells

Indexed keywords

HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; B LYMPHOCYTE; BREAST CARCINOMA; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY GENE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREGULATION; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; OVARY CARCINOMA; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84892384405     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26491     Document Type: Review

References (84)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
2. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294:605-9; PMID:11567106; http://dx.doi.org/10.1126/science.1063916.
3. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-8; PMID:10684858; http://dx.doi. org/10.1084/jem.191.4.661.
4. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A 1987; 84:9145-9; PMID:3480534; http://dx.doi.org/10.1073/pnas.84.24.9145.
5. Koller BH, Geraghty DE, Shimizu Y, DeMars R, Orr HT. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol 1988; 141:897-904; PMID:3260916.
6. Geraghty DE, Wei XH, Orr HT, Koller BH. Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med 1990; 171:1-18; PMID:1688605; http://dx.doi. org/10.1084/jem.171.1.1.
7. Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi EA. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol 2011; 28:3069-86; PMID:21622995; http://dx.doi.org/10.1093/molbev/msr138.
8. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81:199-252; PMID:14711057; http://dx.doi.org/10.1016/S0065-2776(03)81006-4.
9. Rizzo R, Trentini A, Bortolotti D, Manfrinato MC, Rotola A, Castellazzi M, Melchiorri L, Di Luca D, Dallocchio F, Fainardi E, et al. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem 2013; 381:243-55; PMID:23737137; http://dx.doi.org/10.1007/s11010-013-1708-5.
10. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111:4862-70; PMID:18334671; http://dx.doi. org/10.1182/blood-2007-12-127662.
11. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006; 281:10439-47; PMID:16455647; http://dx.doi.org/10.1074/jbc.M512305200.
12. Grimsley C, Kawasaki A, Gassner C, Sageshima N, Nose Y, Hatake K, Geraghty DE, Ishitani A. Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. Tissue Antigens 2002; 60:206-12; PMID:12445303; http://dx.doi. org/10.1034/j.1399-0039.2002.600302.x.
13. Diehl M, Münz C, Keilholz W, Stevanović S, Holmes N, Loke YW, Rammensee HG. Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 1996; 6:305-14; PMID:8805247; http://dx.doi. org/10.1016/S0960-9822(02)00481-5.
14. LeMaoult J, Rouas-Freiss N, Carosella ED. Immunotolerogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun Rev 2005; 4:503-9; PMID:16214086; http://dx.doi. org/10.1016/j.autrev.2005.04.006.
15. Bland FA, Lemberg MK, McMichael AJ, Martoglio B, Braud VM. Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E. J Biol Chem 2003; 278:33747-52; PMID:12821659; http://dx.doi. org/10.1074/jbc.M305593200.
16. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997; 27:1164-9; PMID:9174606; http://dx.doi. org/10.1002/eji.1830270517.
17. Braud VM, Allan DS, Wilson D, McMichael AJ. TAPand tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998; 8:1-10; PMID:9427624; http://dx.doi.org/10.1016/S0960-9822(98)70014-4.
18. Mazzarino P, Pietra G, Vacca P, Falco M, Colau D, Coulie P, Moretta L, Mingari MC. Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-Erestricted fashion. Eur J Immunol 2005; 35:3240-7; PMID:16224817; http://dx.doi.org/10.1002/eji.200535343.
19. Yan WH, Lin A, Chen BG, Chen SY. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J Infect Dis 2009; 200:820-6; PMID:19619059; http://dx.doi. org/10.1086/604733.
20. Rizzo R, Melchiorri L, Stignani M, Baricordi OR. HLA-G expression is a fundamental prerequisite to pregnancy. Hum Immunol 2007; 68:244-50; PMID:17400059; http://dx.doi.org/10.1016/j. humimm.2006.10.012.
21. Zarkhin V, Talisetti A, Li L, Wozniak LJ, McDiarmid SV, Cox K, Esquivel C, Sarwal MM. Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients. Transplantation 2010; 90:1000-5; PMID:20814356; http://dx.doi. org/10.1097/TP.0b013e3181f546af.
22. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum Immunol 2006; 67:561-7; PMID:16916651; http://dx.doi.org/10.1016/j. humimm.2006.03.023.
23. LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, Carosella ED. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003; 62:273-84; PMID:12974794; http://dx.doi. org/10.1034/j.1399-0039.2003.00143.x.
24. Crispim JC, Duarte RA, Soares CP, Costa R, Silva JS, Mendes-Júnior CT, Wastowski IJ, Faggioni LP, Saber LT, Donadi EA. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol 2008; 18:361-7; PMID:18158124; http://dx.doi.org/10.1016/j.trim.2007.10.010.
25. Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, Moreau P, Rouas-Freiss N, Carosella ED. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol 2005; 79:15226-37; PMID:16306594; http://dx.doi. org/10.1128/JVI.79.24.15226-15237.2005.
26. Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, et al. HLA-G,-E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 2000; 61:1177-95; PMID:11137224; http://dx.doi.org/10.1016/S0198-8859(00)00154-3.
27. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65:10139-44; PMID:16287995; http://dx.doi. org/10.1158/0008-5472.CAN-05-0097.
28. Agaugué S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011; 117:7021-31; PMID:21482709; http://dx.doi. org/10.1182/blood-2010-07-294389.
29. Caumartin J, Lemaoult J, Carosella ED. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl Immunol 2006; 17:20-2; PMID:17157208; http://dx.doi.org/10.1016/j.trim.2006.09.032.
30. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, LeMaoult J. Trogocytosisbased generation of suppressive NK cells. EMBO J 2007; 26:1423-33; PMID:17318190; http://dx.doi. org/10.1038/sj.emboj.7601570.
31. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109:2040-8; PMID:17077329; http://dx.doi.org/10.1182/blood-2006-05-024547.
32. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001; 92:369-76; PMID:11466692; http://dx.doi. org/10.1002/1097-0142(20010715)92:2<369::AIDCNCR1332>30.CO;2-U.
33. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 2002; 100:580-5; PMID:12124808; http://dx.doi. org/10.1002/ijc.10524.
34. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9:4460-4; PMID:14555519.
35. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13:371-7; PMID:14708717; http://dx.doi.org/10.1016/S1044-579X(03)00028-2.
36. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the alloproliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A 2001; 98:12150-5; PMID:11572934; http://dx.doi. org/10.1073/pnas.201407398.
37. Emeagi PU, Goyvaerts C, Maenhout S, Pen J, Thielemans K, Breckpot K. Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med 2013; 13:602-25; PMID:22973872; http://dx.doi. org/10.2174/1566524011313040011.
38. Gobin SJ, van Zutphen M, Woltman AM, van den Elsen PJ. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol 1999; 163:1428-34; PMID:10415043.
39. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11:803-11; PMID:10330285; http://dx.doi. org/10.1093/intimm/11.5.803.
40. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159:817-24; PMID:11549573; http://dx.doi.org/10.1016/S0002-9440(10)61756-7.
41. González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 2012; 49:63-84; PMID:22537084; http://dx.doi.org/10.3109/10408363.2012.677947.
42. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and-G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33:125-34; PMID:12594841; http://dx.doi.org/10.1002/immu.200390015.
43. Fons P, Chabot S, Cartwright JE, Lenfant F, L'Faqihi F, Giustiniani J, Herault JP, Gueguen G, Bono F, Savi P, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006; 108:2608-15; PMID:16809620; http://dx.doi.org/10.1182/blood-2005-12-019919.
44. Le Bouteiller P, Fons P, Herault JP, Bono F, Chabot S, Cartwright JE, Bensussan A. Soluble HLA-G and control of angiogenesis. J Reprod Immunol 2007; 76:17-22; PMID:17467060; http://dx.doi. org/10.1016/j.jri.2007.03.007.
45. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19:662-4; PMID:15670976.
46. Bukur J, Malenica B, Huber C, Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 2003; 64:1081-92; PMID:14602239; http://dx.doi. org/10.1016/j.humimm.2003.08.350.
47. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998; 95:4510-5; PMID:9539768; http://dx.doi.org/10.1073/pnas.95.8.4510.
48. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005; 35:1133-42; PMID:15770701; http://dx.doi.org/10.1002/eji.200425741.
49. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci U S A 2008; 105:8357-62; PMID:18550825; http://dx.doi.org/10.1073/pnas.0803341105.
50. Iwaszko M, Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz) 2011; 59:353-67; PMID:21800130; http://dx.doi.org/10.1007/s00005-011-0137-y.
51. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007; 109:2806-14; PMID:17179229.
52. Dong Y, Lieskovska J, Kedrin D, Porcelli S, Mandelboim O, Bushkin Y. Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol 2003; 64:802-10; PMID:12878359; http://dx.doi.org/10.1016/S0198-8859(03)00093-4.
53. Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006; 177:3100-7; PMID:16920947.
54. Teklemariam T, Zhao L, Hantash BM. Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. Hum Immunol 2012; 73:898-905; PMID:22732094; http://dx.doi. org/10.1016/j.humimm.2012.06.007.
55. Ulbrecht M, Couturier A, Martinozzi S, Pla M, Srivastava R, Peterson PA, Weiss EH. Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol 1999; 29:537-47; PMID:10064069; http://dx.doi.org/10.1002/(SICI )1521-4141(199902)29: 02<537: :AIDIMMU537>30.CO;2-6.
56. Ulbrecht M, Kellermann J, Johnson JP, Weiss EH. Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding. J Exp Med 1992; 176:1083-90; PMID:1402654; http://dx.doi. org/10.1084/jem.176.4.1083.
57. Wada H, Matsumoto N, Maenaka K, Suzuki K, Yamamoto K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur J Immunol 2004; 34:81-90; PMID:14971033; http://dx.doi.org/10.1002/eji.200324432.
58. Michaëlsson J, Teixeira de Matos C, Achour A, Lanier LL, Kärre K, Söderström K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002; 196:1403-14; PMID:12461076; http://dx.doi.org/10.1084/jem.20020797.
59. Li J, Goldstein I, Glickman-Nir E, Jiang H, Chess L. Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 2001; 167:3800-8; PMID:11564797.
60. Rabot M, Tabiasco J, Polgar B, Aguerre-Girr M, Berrebi A, Bensussan A, Strbo N, Rukavina D, Le Bouteiller P. HLA class I/NK cell receptor interaction in early human decidua basalis: possible functional consequences. Chem Immunol Allergy 2005; 89:72-83; PMID:16129954; http://dx.doi. org/10.1159/000087914.
61. Jiang H, Canfield SM, Gallagher MP, Jiang HH, Jiang Y, Zheng Z, Chess L. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 2010; 120:3641-50; PMID:20877010; http://dx.doi.org/10.1172/JCI43522.
62. Marín R, Ruiz-Cabello F, Pedrinaci S, Méndez R, Jiménez P, Geraghty DE, Garrido F. Analysis of HLA-E expression in human tumors. Immunogenetics 2003; 54:767-75; PMID:12618909.
63. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 2005; 64:523-8; PMID:15977644.
64. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol 2008; 32:633-41; PMID:18292941.
65. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci U S A 2011; 108:10656-61; PMID:21670276; http://dx.doi.org/10.1073/pnas.1100354108.
66. Wei XH, Orr HT. Differential expression of HLAE, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990; 29:131-42; PMID:2249951; http://dx.doi.org/10.1016/0198-8859(90)90076-2.
67. Le Bouteiller P, Lenfant F. Antigen-presenting function(s) of the non-classical HLA-E,-F and -G class I molecules: the beginning of a story. Res Immunol 1996; 147:301-13; PMID:8876058; http://dx.doi.org/10.1016/0923-2494(96)89643-X.
68. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, Geraghty DE. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003; 171:1376-84; PMID:12874228.
69. Fiszer D, Ulbrecht M, Fernandez N, Johnson JP, Weiss EH, Kurpisz M. Analysis of HLA class Ib gene expression in male gametogenic cells. Eur J Immunol 1997; 27:1691-5; PMID:9247579; http://dx.doi. org/10.1002/eji.1830270715.
70. Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010; 40:2308-18; PMID:20865824; http://dx.doi. org/10.1002/eji.201040348.
71. Lepin EJ, Bastin JM, Allan DS, Roncador G, Braud VM, Mason DY, van der Merwe PA, McMichael AJ, Bell JI, Powis SH, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30:3552-61; PMID:11169396; http://dx.doi. org/10.1002/1521-4141(200012)30:12<3552::AIDIMMU3552>30.CO;2-L.
72. Boyle LH, Gillingham AK, Munro S, Trowsdale J. Selective export of HLA-F by its cytoplasmic tail. J Immunol 2006; 176:6464-72; PMID:16709803.
73. Lee N, Geraghty DE. HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003; 171:5264-71; PMID:14607927.
74. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLAF, and HLA-G. Hum Immunol 2000; 61:1102-7; PMID:11137213; http://dx.doi.org/10.1016/S0198-8859(00)00198-1.
75. Noguchi K, Isogai M, Kuwada E, Noguchi A, Goto S, Egawa K. Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res 2004; 24(5C):3387-92; PMID:15515436.
76. Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, Yan WH. Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer 2013; 132:82-9; PMID:22544725; http://dx.doi.org/10.1002/ijc.27621.
77. Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ, Yan WH. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 2011; 74:504-9; PMID:21561677; http://dx.doi.org/10.1016/j.lungcan.2011.04.006.
78. Contini P, Ghio M, Merlo A, Brenci S, Filaci G, Indiveri F, Puppo F. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Hum Immunol 2000; 61:1347-51; PMID:11163092; http://dx.doi.org/10.1016/S0198-8859(00)00212-3.
79. Bossard C, Bézieau S, Matysiak-Budnik T, Volteau C, Laboisse CL, Jotereau F, Mosnier JF. HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer 2012; 131:855-63; PMID:21953582; http://dx.doi. org/10.1002/ijc.26453.
80. Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G. HLA-E contributes to an immuneinhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol 2012; 250:27-34; PMID:22688424; http://dx.doi.org/10.1016/j.jneuroim.2012.05.010.
81. Allard M, Oger R, Vignard V, Percier JM, Fregni G, Périer A, Caignard A, Charreau B, Bernardeau K, Khammari A, et al. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 2011; 6:e21118; PMID:21712991; http://dx.doi.org/10.1371/journal.pone.0021118.
82. Kren L, Fabian P, Slaby O, Janikova A, Soucek O, Sterba J, Krenova Z, Michalek J, Kral Z. Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract 2012; 208:45-9; PMID:22177730; http://dx.doi.org/10.1016/j. prp.2011.11.004.
83. Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M, Giacomini P. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011; 9:184; PMID:22032294; http://dx.doi. org/10.1186/1479-5876-9-184.
84. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 2012; 10:184; PMID:22947189; http://dx.doi.org/10.1186/1479-5876-10-184.